Outlook Therapeutics
OTLK
12 hedge funds and large institutions have $5.09M invested in Outlook Therapeutics in 2018 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 0 closing their positions.
18% more capital invested
Capital invested by funds: $4.31M → $5.09M (+$774K)
9% more funds holding
Funds holding: 11 → 12 (+1)
0.05% less ownership
Funds ownership: 0.1% → 0.04% (-0.05%)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$232K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$136K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$2.11K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$297K |
| 2 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$20.1K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$3.94K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$1.69K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $3.32M | -$297K | -2,112 | -9% |
|
|
ACA
2
Avoro Capital Advisors
New York
| $670K | – | – | – |
|
|
3
Vanguard Group
Malvern,
Pennsylvania
| $561K | +$232K | +1,649 | +85% |
|
|
MWNA
4
Marshall Wace North America
New York
| $257K | – | – | – |
|
|
5
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $152K | +$136K | +969 | New |
|
|
PAM
6
Panagora Asset Management
Boston,
Massachusetts
| $37K | -$20.1K | -143 | -38% |
|
|
ACP
7
Acuta Capital Partners
Redwood City,
California
| $29K | – | – | – |
|
|
TSS
8
Two Sigma Securities
New York
| $18K | -$3.94K | -28 | -20% |
|
9
Morgan Stanley
New York
| $16K | – | – | – |
|
|
10
Bank of America
Charlotte,
North Carolina
| $12K | +$2.11K | +15 | +24% |
|
11
Geode Capital Management
Boston,
Massachusetts
| $10K | – | – | – |
|
|
12
UBS Group
Zurich,
Switzerland
| $7K | -$1.69K | -12 | -19% |
|
OTLK Hedge Fund Activity: Q3 2018 in Review
12 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q3 2018, worth a combined $5.09M — up 18% from $4.31M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new OTLK positions and 0 closed out — a net gain of 1 holder — while 2 added to existing stakes and 4 trimmed.
The largest buyer was Vanguard Group, adding an estimated $232K. The largest seller was Sabby Management, cutting an estimated $297K.
- 12 institutional investors held Outlook Therapeutics (OTLK) as of Q3 2018, up from 11 in Q2 2018.
- Funds reported $5.09M of Outlook Therapeutics stock for Q3 2018, up 18% quarter-over-quarter.
- 1 fund opened new Outlook Therapeutics positions in Q3 2018 and 0 closed out, a net change of +1 holder.
- The largest Outlook Therapeutics buyer in Q3 2018 was Vanguard Group, an estimated $232K added.
- The largest Outlook Therapeutics seller in Q3 2018 was Sabby Management, an estimated $297K sold.
Based on aggregated 13F filings for Q3 2018.